| Today’s Big NewsNov 17, 2023 |
| By Nick Paul Taylor Karuna Therapeutics has ticked another task off the to-do list for its blockbuster-in-waiting KarXT, posting phase 1b data that counter concerns about the effect of the schizophrenia therapy on blood pressure. |
|
|
|
By Max Bayer,Gabrielle Masson Janet Woodcock is set to retire from the FDA after nearly 40 years at the agency. Madrigal names ex-Sanofi leaders as new CCO. Mural unveils with a pair of seasoned clinical development leaders. |
By Annalee Armstrong Fierce Biotech investigates a biotech caper after Takeda's TAK-279 poster mysteriously went missing from the late-breaker poster session at ACR in San Diego this week. |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
Reduce sequence artifacts that dampen variant calling sensitivity. Prepare highly complex libraries in under 1.5 hours, and minimize damage and loss with precious low-input and FFPE material. Learn more.
|
|
By Ayla Ellison,Fraiser Kansteiner,Annalee Armstrong,Eric Sagonowsky This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
By Annalee Armstrong Cancer drugs are getting better thanks to innovation, driven by the data and regulatory forces like Project FrontRunner. |
By Nick Paul Taylor The backlash against science is continuing, with Pew Research Center tracking a souring of U.S. views of its impact on society and a more than 100% jump in the proportion of U.S. adults who distrust scientists. |
By Conor Hale The over-the-counter Simple 2 test is sold by LetsGetChecked—a former Fierce 15 winner that made a name for itself in remote testing during the COVID-19 pandemic. |
By Zoey Becker Grappling with high demand for several of its new products, Lilly is once again revealing a sizable manufacturing investment. The new manufacturing site in Germany will create up to 1,000 jobs, Lilly confirmed Friday. |
By Dave Muoio Nearly half of surveyed U.S. adults with average or lower incomes said they had a cost-related reason for skipping medical care during the prior 12 months, versus 29% of those with higher incomes. |
By Angus Liu Novartis inked a solid tumor CAR-T deal with Legend Biotech. Astellas is buying a biotech, working to understand deaths in its gene therapy trial and partnering up to drive drug discovery. Ajinomoto will buy a gene therapy CDMO. And more. |
Fierce podcastsDon’t miss an episode |
| | This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
